[go: up one dir, main page]

MX2018000839A - Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos. - Google Patents

Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos.

Info

Publication number
MX2018000839A
MX2018000839A MX2018000839A MX2018000839A MX2018000839A MX 2018000839 A MX2018000839 A MX 2018000839A MX 2018000839 A MX2018000839 A MX 2018000839A MX 2018000839 A MX2018000839 A MX 2018000839A MX 2018000839 A MX2018000839 A MX 2018000839A
Authority
MX
Mexico
Prior art keywords
complex
psa
mhc
same
major histocompatibility
Prior art date
Application number
MX2018000839A
Other languages
English (en)
Inventor
Liu Hong
Xu Yiyang
Xiang Jingyi
Wai- Fan CHAN Vivien
Original Assignee
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eureka Therapeutics Inc filed Critical Eureka Therapeutics Inc
Publication of MX2018000839A publication Critical patent/MX2018000839A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K40/4275—Prostate specific antigen [PSA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente solicitud proporciona construcciones que comprenden una porción de anticuerpo que se une específicamente a un complejo que comprende el péptido PSA y una proteína MHC clase I. También se proporcionan métodos para producir y utilizar estas construcciones.
MX2018000839A 2015-07-22 2016-07-22 Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos. MX2018000839A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195706P 2015-07-22 2015-07-22
PCT/US2016/043753 WO2017015634A2 (en) 2015-07-22 2016-07-22 Constructs targeting psa peptide/mhc complexes and uses thereof

Publications (1)

Publication Number Publication Date
MX2018000839A true MX2018000839A (es) 2018-05-04

Family

ID=57834754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000839A MX2018000839A (es) 2015-07-22 2016-07-22 Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos.

Country Status (10)

Country Link
US (1) US20200087400A1 (es)
EP (1) EP3325517A2 (es)
KR (1) KR20180029253A (es)
AU (1) AU2016297259A1 (es)
CA (1) CA2993185A1 (es)
IL (1) IL256925A (es)
MX (1) MX2018000839A (es)
PH (1) PH12018500159A1 (es)
TW (1) TW201708260A (es)
WO (1) WO2017015634A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018004721A (es) 2015-10-23 2018-07-06 Eureka Therapeutics Inc Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US11613573B2 (en) 2017-04-26 2023-03-28 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
MX2023014984A (es) * 2021-06-17 2024-03-12 Atreca Inc Anticuerpos anti-csp.
US12319747B2 (en) * 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
WO2025171401A2 (en) * 2024-02-09 2025-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against cd99 and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946133B1 (en) * 1996-03-20 2005-09-20 The United States Of America As Represented By The Department Of Health And Human Services Prostate specific antigen oligo-epitope peptide
CA2754764A1 (en) * 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines

Also Published As

Publication number Publication date
PH12018500159A1 (en) 2018-07-23
WO2017015634A2 (en) 2017-01-26
TW201708260A (zh) 2017-03-01
CA2993185A1 (en) 2017-01-26
WO2017015634A3 (en) 2017-03-09
AU2016297259A1 (en) 2018-02-08
IL256925A (en) 2018-03-29
US20200087400A1 (en) 2020-03-19
EP3325517A2 (en) 2018-05-30
KR20180029253A (ko) 2018-03-20

Similar Documents

Publication Publication Date Title
MX2017016838A (es) Construcciones dirigidas a complejos de peptido de ny-eso-1/complejo principal de histocompatibilidad (mhc) y usos de los mismos.
MX2018000839A (es) Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos.
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
CY1125241T1 (el) Υποδορια σκευασματα αντισωματων anti-cd38 και οι χρησεις τους
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
BR112018014760A2 (pt) anticorpos anti-ror1, anticorpos biespecíficos para ror1 x cd3 e métodos de uso dos mesmos
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
CO2020012347A2 (es) Anticuerpos anti-hla-g y usos de los mismos.
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
MX2019004690A (es) Constructos de anticuerpos.
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
BR112019012343A2 (pt) anticorpos il-11ra
UY35964A (es) Anticuerpos humanos para pd?1
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
MX2017001597A (es) Anticuerpos anti-pd-l1.
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
MX2013013832A (es) Proteínas de unión receptoras fc.
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN